为何吸入性抗生素治疗呼吸机相关性肺炎的品种有限
综述探讨吸入性抗生素(IA)治疗呼吸机相关性肺炎(VAP)的证据。2016年IDSA/ATS指南基于9项研究的荟萃分析(RR 1.29;95% CI 1.13-1.47)推荐辅助IA用于仅对氨基糖苷类或多粘菌素敏感的革兰阴性杆菌所致VAP。后续两项随机试验未显示获益,但纳入这两项试验的更新荟萃分析(n=11)仍提示辅助IA对MDR和难治性感染VAP有益(RR 1.2;95% CI 1.05-1.57)。
要点
- 2016 IDSA/ATS指南推荐辅助吸入性抗生素用于仅对氨基糖苷类或多粘菌素敏感的革兰阴性杆菌所致VAP。
- 两项后续随机试验未证实辅助吸入性抗生素的获益。
- 更新荟萃分析(n=11)提示辅助吸入性抗生素对MDR和难治性感染VAP有益(RR 1.2;95% CI 1.05-1.57)。
核心结论
- 静脉抗生素选择有限的VAP患者最可能从辅助吸入性抗生素中获益,应作为未来研究重点。
研究设计与样本
- 综述检索了2016年IDSA/ATS医院获得性肺炎指南委员会所做的荟萃分析以及PubMed和ClinicalTrials.gov上后续的吸入性抗生素治疗VAP试验。
主要发现
- 2016年指南委员会基于9项研究的荟萃分析(RR 1.29;95% CI 1.13-1.47)推荐辅助吸入性抗生素用于仅对氨基糖苷类或多粘菌素敏感的革兰阴性杆菌所致VAP。
- 两项后续随机试验未能证明辅助吸入性抗生素对机械通气肺炎患者有益。
- 更新的荟萃分析(n=11)纳入这两项近期试验后,提示辅助吸入性抗生素对MDR和难治性感染所致VAP有益(RR 1.2;95% CI 1.05-1.57)。
关键数值与推荐
- 2016年IDSA/ATS指南推荐:辅助吸入性抗生素用于治疗仅对氨基糖苷类或多粘菌素敏感的革兰阴性杆菌所致VAP。
- 更新荟萃分析(n=11)显示辅助吸入性抗生素对MDR和难治性感染VAP的RR为1.2(95% CI 1.05-1.57)。
临床怎么用
- 对于静脉抗生素选择有限的VAP患者,可考虑辅助吸入性抗生素治疗。
局限性
- 振动网孔雾化器在药企赞助的试验中占主导,但未与传统的喷射雾化器在疗效或安全性方面进行直接比较。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The increasing prevalence of ventilator-associated pneumonia (VAP) due to either multidrug-resistant (MDR) organisms or infections with limited treatment options (i.e. susceptible to only aminoglycosides or colisitin) coupled with a dearth of new antimicrobials has led clinicians to pursue alternative management strategies including the use of inhaled antibiotics (IA). OBJECTIVES: To review the evidence surrounding the use of IA in the treatment of VAP with a focus on establishing a path whereby adjunctive IA could become a standard therapy for the treatment of specific VAP patient populations. SOURCES: A meta-analysis performed by the 2016 IDSA/ATS Hospital-acquired Pneumonia Guideline Committee; a PubMed and clinicaltrials.gov search for subsequent trials of IA for the treatment of VAP. CONTENT: Based on a meta-analysis of nine studies (RR 1.29; 95% CI 1.13-1.47), the 2016 IDSA/ATS Hospital-acquired Pneumonia Guideline Committee recommended that adjunctive IA be used to treat VAP due to Gram-negative bacilli that are susceptible to only aminoglycosides or polymyxins. Two subsequent randomized trials of adjunctive IA for the treatment of mechanically ventilated patients with pneumonia failed to demonstrate a benefit. Despite these results, an updated meta-analysis (n = 11) including these two recent trials suggests a benefit of adjunctive IA for the treatment of VAP due to MDR and difficult-to-treat infections (RR 1.2; 95% CI 1.05-1.57). IMPLICATIONS: Patients with VAP and limited intravenous antibiotic options are the individuals most likely to benefit from adjunctive IA and should be the focus of future investigative studies. Although vibrating mesh nebulizers predominate in pharmaceutical company-sponsored trials, these devices have not been directly compared with the traditional jet nebulizers in terms of efficacy or safety.
引用
- Sweeney DA, Kalil AC. Why don't we have more inhaled antibiotics to treat ventilator-associated pneumonia? Clin Microbiol Infect. 2019. PMID: 31035015. doi:10.1016/j.cmi.2019.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。